Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer. [electronic resource]
Producer: 20200303Description: 1116-1124 p. digitalISSN:- 2005-6648
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Anaplastic Lymphoma Kinase -- antagonists & inhibitors
- Antineoplastic Agents -- adverse effects
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Clinical Decision-Making
- Crizotinib -- adverse effects
- Decision Support Techniques
- Disease Progression
- Female
- Humans
- Lung Neoplasms -- drug therapy
- Male
- Middle Aged
- Progression-Free Survival
- Protein Kinase Inhibitors -- adverse effects
- Reproducibility of Results
- Risk Assessment
- Risk Factors
- Time Factors
- Young Adult
No physical items for this record
Publication Type: Journal Article; Validation Study
There are no comments on this title.
Log in to your account to post a comment.